Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Rating of “Hold” from Brokerages

Aytu BioPharma Inc. (NASDAQ:AYTU) has been assigned a consensus recommendation of “Hold” from the five research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.75.

A number of research analysts recently commented on the stock. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Ascendiant Capital Markets upped their price target on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th.

Institutional Investors Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in AYTU. Dimensional Fund Advisors LP grew its stake in shares of Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after buying an additional 8,222 shares in the last quarter. BlackRock Inc. bought a new position in Aytu BioPharma during the second quarter valued at approximately $49,000. Persistent Asset Partners Ltd acquired a new stake in Aytu BioPharma in the second quarter valued at approximately $82,000. Arete Wealth Advisors LLC acquired a new stake in Aytu BioPharma in the first quarter valued at approximately $135,000. Finally, Crown Advisors Management Inc. bought a new stake in Aytu BioPharma in the second quarter worth approximately $430,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Stock Up 4.7%

NASDAQ AYTU traded up $0.10 during trading on Tuesday, reaching $2.23. 273,446 shares of the company’s stock were exchanged, compared to its average volume of 49,528. Aytu BioPharma has a fifty-two week low of $1.65 and a fifty-two week high of $3.07. The firm has a market capitalization of $23.93 million, a PE ratio of -0.49 and a beta of 0.26. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $2.21 and its 200-day simple moving average is $2.33.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Tuesday, September 22nd. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.24. The company had revenue of $16.11 million for the quarter, compared to analysts’ expectations of $12.28 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. Sell-side analysts predict that Aytu BioPharma will post -0.73 EPS for the current year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.